Consistent Double-Digit Revenue Growth
Quanterix reported a sixth consecutive quarter of double-digit revenue growth with Q3 2024 revenue increasing by 13% to $35.7 million.
Strong Performance in Accelerator Lab
Accelerator Lab revenue increased by 36%, reaching $10.5 million, driven by clinical trials and custom assay development.
Significant Advances in Alzheimer's Disease Testing
Launch of LucentAD Complete, a multi-marker assay, showing strong interest and promising results in Alzheimer's diagnostics with accuracy above 90%.
Expansion of Product Portfolio
Commercialization of 16 new products year-to-date, with plans to launch 4 more assays by the end of the year.
Positive Cash and Liquidity Position
Nearly $300 million in liquidity with reduced cash usage to $3 million in the quarter.